Recursion Pharmaceuticals (RXRX) Shares Outstanding (Diluted Average) (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $529.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 31.42% year-over-year to $529.3 million; the trailing twelve-month figure through Mar 2026 stood at $529.3 million (up 31.42% YoY), and the FY2025 full-year result was $447.4 million, up 63.18% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $529.3 million, up from $447.4 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $529.3 million in Q1 2026 and bottomed at $170.7 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $236.0 million (2024), against an average of $281.3 million.
• Peak annual rise in Shares Outstanding (Diluted Average) reached 640.98% in 2022, while the deepest fall reached 2.91% in 2022.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $175.5 million in 2022, then rose by 18.41% to $207.9 million in 2023, then soared by 31.92% to $274.2 million in 2024, then jumped by 63.18% to $447.4 million in 2025, then gained by 18.29% to $529.3 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $529.3 million (Q1 2026), $447.4 million (Q4 2025), and $447.0 million (Q3 2025), per Business Quant data.

Peer Comparison